Renal Cell Carcinoma
From the Journals
Immunotherapy enables nephrectomy with good outcomes in advanced RCC
Patients able to undergo nephrectomy after receiving immune checkpoint inhibitors had favorable surgical outcomes and pathologic responses in the...
From the Journals
Cancer burden: Multiple metrics needed to clarify the big picture
A cancer’s so-called epidemiologic signature – the composite pattern of incidence, mortality, and metastatic incidence – helps sort out the...
From the Journals
No difference between ipilimumab/nivolumab combo and immunotherapy plus VEGF for metastatic RCC
Therefore, the treatment should probably be directed by patient preferences, among other things, the investigators said.
From the Journals
PBRM1 mutations not quite up to snuff as ccRCC biomarkers
Truncating mutations in PBRM1 are moderately linked to response to immune checkpoint inhibitors in metastatic clear cell renal cell carcinoma.
From the Journals
SABR offers surgery alternative for localized RCC
Patients with smaller tumors had the best outcomes.
From the Journals
Nivolumab falls short in ccRCC patients with brain metastases
Nivolumab produced an intracranial response rate of 12% in patients with clear cell renal cell carcinoma and previously untreated brain metastases...
From the Journals
Study outlines survival factors with nivolumab
Absence of bone or liver metastases and excellent baseline performance status are linked to 5-year OS in melanoma, RCC, and NSCLC treated with...
News
FDA approves bevacizumab-bvzr for several cancers
The bevacizumab biosimilar is now approved for metastatic colorectal cancer, advanced non-squamous non–small cell lung cancer, recurrent...
Conference Coverage
Nephrectomy may benefit select renal cancer patients based on risk factors
CHICAGO – CARMENA update confirms cytoreductive nephrectomy should not be standard of care for most cases of metastatic renal cell carcinoma.
Conference Coverage
Trial matches pediatric cancer patients to targeted therapies
Nearly a quarter of the patients screened as part of the National Cancer Institute–Children’s Oncology Group Pediatric MATCH trial have been...
From the Journals
Model shows nivolumab plus ipilimumab cost effective in mRCC
A subgroup analysis indicated that nivolumab plus ipilimumab was most cost effective for patients with 1% or greater PD-L1 expression.